drugset / Trial / NCT02730416
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Phase 2
Completed
146 enrolled
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
ARCAGY/ GINECO GROUP · collabBelgian Gynaecological Oncology Group · collabNorth Eastern German Society of Gynaecological Oncology · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the role of addition of an anti-angiogenic agent (Nintedanib/placebo) to conventional combination chemotherapy as concomitant and maintenance treatment in primary advanced or with first relapse of endometrial cancer.
Timeline
- Start
- 2016-12-12
- Primary completion
- 2021-10-20
- Completion
- 2021-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 200 mg | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |